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Plasma adiponectin as a predictive factor of
survival after a bypass operation for peripheral
arterial disease
Hiroyoshi Komai, MD,a Rei Shibata, MD, PhD,b Masanobu Juri, MD,a Kunihiro Matsushita, MD,b
Noriyuki Ouchi, MD, PhD,c and Toyoaki Murohara, MD, PhD,b Wakayama and Nagoya, Japan; and
Boston, Mass
Objective: We investigated an association between adiponectin and long-term survival in patients requiring an arterial
bypass operation for peripheral arterial disease.
Methods: An enzyme-linked immunosorbent assay kit was used to measure plasma adiponectin levels in 49 patients (38
men, 11 women) before they underwent an arterial bypass operation. Median patient age was 70 years (range, 49-90
years). The study excluded patients with hemodialysis requirement, heart failure, malignant neoplasm, or collagen
disease. The symptoms at the first visit were severe intermittent claudication in 27 patients (55%) and critical limb
ischemia with rest pain or ulcer, or both, in 22 (45%).
Results: Plasma adiponectin levels were a mean 7.8 5.3 g/mL (range, 1.0-25.2 g/mL). Multiple regression analyses
revealed that plasma adiponectin was positively correlated with age (r 0.49, P  .0003) and negatively correlated with
body mass index (r  0.51, P  .0002) and systolic blood pressure (r  0.41, P  .0059). The Cox proportional
hazards model revealed that plasma adiponectin (hazard ratio, 1.30; P  .03) and critical limb ischemia (hazard ratio,
16.67; P  .047) were significant independent predictors of patient survival after a bypass operation.
Conclusion: Plasma adiponectin could be indicative of mortality after a bypass operation for patients with advanced
peripheral arterial disease. ( J Vasc Surg 2009;50:95-9.)Peripheral arterial disease (PAD) is a progressive ath-
erosclerotic condition that affects approximately 27 million
people in North America and Europe; however, its mech-
anism of progression is not fully understood. The reported
risk factors for atherosclerosis are diabetes mellitus, hyper-
tension, dyslipidemia, and smoking, but prognostic factors
for patients with PAD have not been clearly determined.
Lipid-related metabolism was recently shown to be
strongly associated with the prognosis of atherosclerosis.
During a 24-month period, outcome events of PAD oc-
curred more frequently in patients with metabolic syn-
drome or obesity than in patients without these diagnoses.1
Waist circumference was an independent predictor of the
likelihood of PAD outcome events in claudicant patients.1
Adiponectin is a fat-derived secreted protein that is
abundantly present in human plasma.2,3 Adiponectin con-
tains a collagen-repeat domain at the N terminus and a
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mology to collagens VIII and X, and compliment factor
C1q. Adiponectin levels are negatively regulated by accu-
mulation of body fat.4 In this regard, plasma adiponectin
levels are low in obese individuals.5 Hypoadiponectinemia
has been clinically identified as a risk factor for the devel-
opment of type 2 diabetes mellitus,6 coronary artery dis-
ease,7 and hypertension.8 Increasing evidence from exper-
imental studies indicates that adiponectin protects against
the development of diabetes mellitus, hypertension, and
cardiovascular disease.
Thus, adiponectin could act as a key molecule for
clarifying the pathogenesis of obesity-linked disorders. Re-
cent prospective studies demonstrated that low adiponectin
levels are an independent predictor of death in patients with
stroke.9 Conversely, high plasma adiponectin levels were a
positive predictor of death in patients with chronic heart
failure.10
Plasma adiponectin was reported to be significantly
lower in patients with early-stage PAD than in patients
without PAD and was independently associated with the
ankle-brachial index (ABI).1,11 However, the relationship
between adiponectin level and the prognosis of PAD pa-
tients has not been fully investigated. Here, we investigated
the association of plasma adiponectin with the survival of
PAD patients requiring an arterial bypass operation. We
hypothesized that plasma adiponectin could be a determi-
nant factor of patients’ long-term survival after a bypass
operation for PAD, which represents one of the end-stage
conditions of generalized atherosclerosis.
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The study enrolled 50 consecutive patients with PAD
who underwent an arterial bypass operation at Saiseikai
Wakayama Hospital. They were diagnosed with PAD by
peripheral arteriography and their clinical symptoms.
One patient was lost to follow-up at an early stage; thus,
49 patients (38 men, 11 women) were finally analyzed.
The patients were a median age of 70 years (range, 49-90
years). The study excluded hemodialysis patients and
those with heart failure, malignant neoplasm, or collagen
disease because these comorbidities are known to affect
plasma adiponectin levels.
The symptoms at the first visit to our hospital were
severe intermittent claudication in 27 patients (55%) and
critical limb ischemia with rest pain or ulcer, or both, in 22
(45%), noted as Fontaine 2 in 27, Fontaine 3 in four, and
Fontaine 4 in 18. The concomitant diseases were type 2
diabetes mellitus in 28 patients (57%), hypertension in 38
(78%), dyslipidemia in 17 (35%), ischemic heart disease in
20 (41%), and symptomatic cerebrovascular disease in 12
(24%) (Table I).
Diabetes mellitus was defined according to the World
Health Organization criteria. Hypertension was defined as
systolic blood pressure of 140 mm Hg or diastolic blood
pressure of 90 mm Hg on repeated measurements, or
receiving antihypertensive treatment. Dyslipidemia was de-
fined as levels of total cholesterol 220 mg/dL or triglyc-
eride 150 mg/dL, or receiving lipid-lowering therapy.
Ischemic heart disease was diagnosed by the existence of
significant stenosis or occlusion in preoperative coronary
angiography.
All patients underwent peripheral artery bypass graft-
ing. An artificial graft was used in 22 patients, and an
autologous vein was used in 27. The operations comprised
an aortobifemoral bypass in 8 patients, a femorofemoral
crossover bypass in 7, a femoropopliteal bypass in 17, and a
tibial bypass in 17.
Routine laboratory results and body mass index (BMI)
Table I. Clinical characteristics of the 49 study
participants
Variable No. or mean  SD








Ischemic heart disease 20
Cerebrovascular disease 12
Systolic blood pressure, mm Hg 140  19
Total cholesterol, mg/dL 194.1  37.0
Triglyceride, mg/dL 129.7  83.2
Creatinine, mg/dL 1.1  0.8was recorded. After patients provided informed consent,venous blood samples were obtained before the operation,
and the plasma adiponectin levels were determined using an
adiponectin enzyme-linked immunosorbent (ELISA) kit
(Otsuka Pharmaceutical Co Ltd, Tokyo, Japan).
After the operation, the patients were followed up at
our outpatient clinic at intervals of 3 to 6 months. Anti-
thrombotic treatment was prescribed in all patients postop-
eratively with one or a combination of following agents:
aspirin, cilostazol, eicosapentaenoic acid, and iloprost. Six
patients were prescribed lipid-lowering agents and 15 re-
ceived angiotensin-converting enzyme inhibitors.
The results were expressed as the mean  standard
deviation (SD). The plasma adiponectin levels were com-
pared among subgroups using a t test for unpaired vari-
ables. The correlations between plasma adiponectin and the
indicated parameters were examined by multiple regression
analyses. The survival rate was calculated with the Kaplan-
Meier method. A survival analysis was performed with the
multivariable Cox proportional hazards model. Differences
were considered to be significant at P  .05.
RESULTS
Plasma adiponectin levels in PAD patients. The
clinical characteristics of the patients are summarized in
Table I. The mean plasma adiponectin level was 7.8  5.3
g/mL (range, 1.0-25.2 g/mL) and did not differ ac-
cording to gender; symptoms of leg ischemia (claudication
or critical limb ischemia); presence of diabetes mellitus,
hypertension, dyslipidemia, or ischemic heart disease; and
history of cerebral vascular disease or tobacco smoking
Table II. Adiponectin level in subgroups
Subgroup Adiponectin levela P
Gender .17
Male 7.3  4.3
Female 9.8  7.7
Severity of leg ischemia .20
Claudication 7.0  4.6
Critical limb ischemia 8.9  5.9
Diabetes mellitus .33
Yes 7.2  5.5
No 8.7  4.9
Hypertension .82
Yes 7.9  5.6
No 7.5  3.9
Dyslipidemia .17
Yes 6.4  4.1
No 8.6  5.7
Ischemic heart disease .61
Yes 7.1  4.7
No 7.8  5.0
Cerebrovascular disease .66
Yes 7.3  6.1
No 8.0  5.0
History of tobacco smoking .14
Yes 7.2  4.4
No 9.7  7.1
aData are presented as the mean g/mL  standard deviation.(Table II). The plasma adiponectin levels were not corre-
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nine, but were positively correlated with age (r 0.49, P
.0003) and negatively correlated with BMI (r –0.51, P
.0002) and systolic blood pressure (r –0.41, P .0059;
Table III).
Plasma adiponectin levels and prognosis of the by-
pass graft. During the mean follow-up of 3.3 years, graft
occlusion occurred in 20 patients. The primary graft pa-
tency rate was 61.2%, and the secondary patency rate was
74.8% for 3 years. To determine independent predictors of
graft patency, the Cox proportional hazards model was
used to analyze plasma adiponectin, age, BMI, systolic
blood pressure, serum creatinine, total cholesterol, triglyc-
eride, symptoms of leg ischemia, association of diabetes
mellitus or ischemic heart disease, history of tobacco smok-
ing, and type of operation, the number of patent tibial
run-off vessels. None of these factors was significantly asso-
ciated with the primary or secondary patency rate.
Plasma adiponectin levels and survival. A total of 12
patients died during the follow-up period. Perioperative
mortality was not different among the different type of
operation (data not shown). Cox proportional hazards
model analysis of plasma adiponectin, age, BMI, systolic
blood pressure, serum creatinine, total cholesterol, triglyc-
eride, symptoms of leg ischemia, association of diabetes or
ischemic heart disease, and history of tobacco smoking
revealed that plasma adiponectin (hazard ratio, 1.30; P 
.03) and critical limb ischemia (hazard ratio, 16.67; P 
.047) were significant independent predictors of survival of
PAD patients after a bypass operation (Table IV). The Fig
Table III. Adiponectin level and clinical parameters
Variable r P
Age 0.49 .0003
Body mass index 0.51 .0002
Systolic blood pressure 0.41 .0059
Total cholesterol 0.02 .89
Triglyceride 0.19 .20
Serum creatinine 0.23 .11
Table IV. Mortality during follow-up analyzed with
multivariable Cox proportional hazard analysis
Variable HR (95% CI) P
Age 0.96 (0.83-1.12) .624
Body mass index 1.06 (0.69-1.64) .783
Systolic blood pressure 1.03 (0.96-1.10) .379
Severity of leg ischemia (CLI) 16.7 (1.03-271) .047
Diabetes mellitus (yes) 1.34 (0.18-9.09) .794
Ischemic heart disease (yes) 2.78 (0.34-25) .339
History of tobacco smoking (yes) 3.59 (0.07-25) .814
Adiponectin 1.30 (1.03-1.66) .030
Total cholesterol 0.99 (0.96-1.03) .737
Triglyceride 0.99 (0.96-1.01) .226
CI, Confidence interval; CLI, critical limb ischemia; HR, hazard ratio.shows the survival curves of patients with plasma adiponec-tin levels of the first (4.0 g/mL; n  11), the second
(4.0 to 6.0 g/mL; n 11), the third (6.0 to 10.7
g/mL; n  15), and the fourth quartile (10.7 g/mL;
n 12). The survival rate of patients in the fourth quartilewas
significantly worse than in the other three quartiles (P .042)
according to Kaplan-Meier analysis and the Mantel-Cox
test.
DISCUSSION
The present study is the first, to our knowledge, to
examine the association between plasma adiponectin and
death in PAD patients after a bypass operation. In this
study, high plasma adiponectin levels were independently
associated with an increased risk of death in PAD patients
who underwent a bypass operation.
Adiponectin is generally reported to act in an anti-
inflammatory, antidiabetic, and antiatherogenic fashion.
The plasma adiponectin levels did not differ between pa-
tients with claudication and those with critical limb isch-
emia. Furthermore, no significant differences were noted
for the associated atherosclerotic risk factors. We speculate
that these findings resulted because we recruited patients
with relatively severe PAD. Specifically, our indications for
a bypass operation are so restricted that the symptoms were
quite severe even in patients with claudication.
Several studies have investigated adiponectin levels in
PAD patients. Golledge et al1 reported that serum adi-
ponectin was positively correlated with the ABI, maximum
walking distance, and initial claudication distance. Their
participants were limited to patients with claudication.
Iwashima et al11 reported a positive correlation of plasma
adiponectin with the ABI and a negative correlation with
the Fontaine stage; however, few of their participants ap-
peared to have critical limb ischemia. Their average ABI was
0.61, and the average Fontaine stage was 1.8, whereas 45%
of our participants had critical limb ischemia and all of our
patients required a bypass operation.
It may be true that plasma adiponectin is negatively
correlated with the severity of PAD in the early stage of the
disease, but this may not be the case in more severely
affected patients. Plasma adiponectin was positively corre-
lated with age and negatively correlated with BMI and
systolic blood pressure in our study, consistent with many
previous reports and supporting the validity of our data set.
Because adiponectin plays a favorable role in the re-
modeling of endothelial function12 and acts in an anti-
inflammatory fashion,13 the plasma adiponectin level may
affect the prognosis of graft patency. We found no relation-
ship between the initial plasma adiponectin level and the
fate of the graft. On the other hand, a high level of plasma
adiponectin was an independent predictor of all causes of
death after a bypass operation. A positive correlation be-
tween plasma adiponectin and a poor survival rate was
observed, and patients with plasma adiponectin levels lower
than the third quartile had a better prognosis than those
higher than the fourth quartile. Thus, adiponectin repre-
sents a useful biomarker for assessment of death in patients
with severe PAD who undergo bypass surgery.
ant
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considering the anti-inflammatory, antidiabetic, and anti-
atherosclerotic properties of adiponectin. In patients with
established chronic heart failure (CHF), high serum adi-
ponectin levels were independently predictive of death.
Tsutamoto et al14 suggested that higher adiponectin levels
could be a marker of the wasting process in CHF, based on
the finding that weight loss increases plasma adiponectin.
Kistorp et al10 found the same relationship between adi-
ponectin and survival of patients with advanced CHF.
Similar results were obtained by George et al,15 who spec-
ulated that high adiponectin levels may represent an expres-
sion of high energy expenditure.
High adiponectin levels were a determinant factor of
death in patients presenting with chest pain,16 and the
authors suggested that high adiponectin levels might reflect
counter-regulatory or compensatory increases, or occur as a
consequence of resistance at the adiponectin receptor level.
PAD patients who require a bypass operation likely have
elevated energy waste to maintain the whole body condi-
tion against the progress of atherosclerosis. It is also possi-
ble that clearance of adiponectin is impaired in severe PAD,
presumably due to downregulation or dysfunction of adi-
ponectin receptors and that at this stage, adiponectin no
longer has vascular protective actions due to decreased
sensitivity of adiponectin to the vasculature or reduced
levels of the functionally active form of adiponectin. Irre-
spective of the possible explanations, however, the mecha-
nism of how high levels of adiponectin are associated with
death in PAD patients is still unknown. Because our results
are obtained from an observational study, future studies
will be needed to explain why patients with higher levels of
a seemingly protective factor show a higher rate of death.
The present study has several limitations. The sample
size was relatively small. Adiponectin levels did not corre-
late with graft outcomes, although the graft patency rate
was not excellent. It might not be reasonable to estimate
graft-related outcomes from such disparate patient groups.
The magnitude of the hazard ratio was higher for
Fig. Survival curves are shown for patients with plasma
second (4.0 to 6.0 mg/mL, n  11), the third (6.0
mg/mL, n 12). Survival rate of patients in the fourth q
(P  .042) according to Kaplan-Meier analysis and the Mischemic heart disease or diabetes mellitus, but we couldnot find statistical significance for these variables, which
could be a strong predictor for survival after bypass opera-
tion.17 Future prospective studies involving larger popula-
tions with homogeneous patients are therefore required.
Some agents that may increase the plasma adiponectin
level, such as antidiabetic18 and antihyperlipidemic drugs,19
were used in the present study and may have affected the
results.
Finally, we intentionally excluded patients with end-
stage renal failure who required hemodialysis. PAD with
hemodialysis is the most serious condition associated with
this disease and has the worst survival,20 although a recent
improvement in graft patency was reported.21,22 The con-
tribution of adiponectin to the mortality rate of hemodial-
ysis patients remains to be elucidated in future studies.
CONCLUSION
High plasma adiponectin levels are independently asso-
ciated with an increased risk of death in PAD patients who
undergo a bypass operation. In the high-risk population,
adiponectin, an antiatherosclerotic protein by nature, ad-
versely predicted patient survival, similar to the case for
CHF patients and patients presenting with chest pain.
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